Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer

Results

Title:	Patient-reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer
Authors:	Conte PierFranco; Schneeweiss Andreas; Loibl Sibylle; Mamounas Eleftherios; von Minckwitz Gunter; Mano Max S; Untch Michael; Huang Chiun-Sheng; Wolmark Norman; Rastogi Priya; D'Hondt Veronique; Redondo Andres; Stamatović Ljiljana; Bonnefoi Hervé; Castro-Salguero Hugo; Fischer Hans H; Wahl Tanya; Song Chunyan; Boulet Thomas; Trask Peter; Geyer Charles E Jr.;
Issue Date:	2020
Publication:	Cancer 126(13) 3132-3139
ISSN:	0008-543X Cancer Search Idenfier
Type:	Article
Collation:	vol. 126 br. 13 str. 3132-3139
DOI:	10.1002/cncr.32873
WoS-ID:	000525904300001
Scopus-ID:	2-s2.0-85083380575
PMID:	32286687
PMCID:	PMC7317721
URI:	https://zenodo.org/record/4773213 https://enauka.gov.rs/handle/123456789/597578
Project:	pmcid:PMC7317721 gnd:gnd:1097-0142.
M-category:	21aM21a

25
SCOPUS^TM

13
PubMed Central^TM

8
OpenCitations

21
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall